Noah Labs

Noah Labs is a Berlin- and Potsdam-based digital health company developing remote monitoring software for chronic cardiovascular conditions. Its commercial product, Noah Labs Ark, is a Class IIa medical device software under the EU Medical Device Regulation that consolidates data from external medical devices (smartwatches, ECGs, weight scales, blood pressure cuffs) and cardiac implants from multiple ICD manufacturers into a single clinician dashboard, together with a patient app. The platform's primary indication is heart failure, with additional live use in atrial fibrillation telemonitoring after ablation or pharmacological therapy, and stated clearance covering further disease areas including metabolic and pulmonary conditions via integration of ECGs, glucose sensors and spirometers.

The company's second technology line is Noah Labs Vox, a deep learning algorithm trained on proprietary audio datasets that detects impending cardiac decompensation from changes in a patient's voice caused by pulmonary edema and vocal fold edema. The company states detection up to 14 days (and, in its Vox product materials, 21 days) before current standard methods, with the stated goal of reducing heart failure hospitalizations by 50%. Patients record voice samples through the Noah Labs app and alerts surface in the Ark dashboard. Noah Labs states that Vox is undergoing clinical investigation and is not yet cleared for medical use; it received FDA Breakthrough Device Designation in March 2026.

Noah Labs describes itself as an ISO 13485 certified manufacturer of software-based medical devices. It runs or participates in several clinical studies: VAMP-HF (Prof. Gerhard Hindricks; launched December 2023 at Mayo Clinic and Charité), PRE-DETECT-HF (Prof. Hans Peter Brunner-La Rocca; EIT Health and EU co-funded, with Maastricht UMC and Clinic Barcelona, first patient enrolled 2025), and TIM-HF III (Prof. Friedrich Köhler), which uses 18 months of weekly voice recordings from chronic heart failure patients monitored at home.

Founding story

Noah Labs was founded in Berlin in 2021 by Oliver Piepenstock (CEO) and Marcus Hott (CTO), who met through the Entrepreneur First incubator program in London. Marcus, a machine learning specialist who programmed cardiac MRI sequences at Harvard Medical School and holds a Master's in Machine Learning from TU Munich, was inspired by that research to apply AI in cardiology. Oliver, a public health expert with a Master's in Finance from Copenhagen Business School, had previously founded the care platform Mecasa. Dr. Leonhard Riehle, a physician with cardiology and pulmonology experience at Charité Berlin who ran telemonitoring programs and researched voice as a digital biomarker, joined as co-founder and Chief Medical Officer.

Business model

Noah Labs sells medical device software to healthcare providers. Its Ark platform is offered to clinics and cardiology practices, with the company handling device logistics and patient onboarding: providers enroll patients with one click, Noah Labs ships monitoring devices within 48 hours, and vital signs and symptoms flow to the provider with abnormality alerts. Telemonitoring can be delegated to physician assistants or qualified medical personnel.

Company materials reference reimbursement pathways rather than pricing: heart failure telemonitoring is described as carrying on-top-of-budget reimbursement for publicly and privately insured patients in Germany, and atrial fibrillation telemonitoring as KHZG-financed. The company also draws on public grant funding (ProFIT Brandenburg, EIT Health, EIC Accelerator).

Traction

The company reports 40,000+ patient days monitored, an 87% patient adherence rate, healthcare provider satisfaction of 93/100, patient satisfaction of 96/100, and use in 75+ clinics in active practice. Noah Labs Ark received EU MDR Class IIa approval in April 2024 and was commercialized in 2024; the company employed 20 people as of its 2024/2025 seed announcement. Vox milestones include FDA Breakthrough Device Designation (March 2026) and late-breaking TIM-HF3 data announced May 2026.

Latest developments

In May 2025 Noah Labs was selected for the European Innovation Council Accelerator program, securing up to €11 million in funding. In March 2026 Noah Labs Vox received FDA Breakthrough Device Designation, and in May 2026 the company announced late-breaking TIM-HF3 data reporting that AI-based voice analysis predicts heart failure hospitalization weeks in advance. The company also completed the Google for Startups Growth Academy: AI for Health in 2025.